Christine Schmid-Tannwald to Liver Neoplasms
This is a "connection" page, showing publications Christine Schmid-Tannwald has written about Liver Neoplasms.
Connection Strength
3.962
-
Role of diffusion-weighted imaging in response prediction and evaluation after high dose rate brachytherapy in patients with colorectal liver metastases. Radiol Oncol. 2024 Mar 01; 58(1):33-42.
Score: 0.613
-
Quantitative SSTR-PET/CT for predicting response and survival outcomes in patients with pancreatic neuroendocrine tumors receiving CAPTEM. Radiol Oncol. 2023 12 01; 57(4):436-445.
Score: 0.604
-
Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT. Diagn Interv Imaging. 2024 Jan; 105(1):15-25.
Score: 0.588
-
Apparent diffusion coefficients (ADC) in response assessment of transarterial radioembolization (TARE) for liver metastases of neuroendocrine tumors (NET): a feasibility study. Acta Radiol. 2022 Jul; 63(7):877-888.
Score: 0.511
-
Diffusion-weighted MRI Before and After Robotic Radiosurgery (Cyberknife®) in Primary and Secondary Liver Malignancies: A Pilot Study. Technol Cancer Res Treat. 2015 Apr; 14(2):191-9.
Score: 0.323
-
DW-MRI of liver lesions: can a single ADC-value represent the entire lesion? Clin Radiol. 2014 May; 69(5):492-8.
Score: 0.308
-
Diffusion-weighted MRI of metastatic liver lesions: is there a difference between hypervascular and hypovascular metastases? Acta Radiol. 2014 Jun; 55(5):515-23.
Score: 0.296
-
Diffusion-weighted MR imaging of focal liver lesions in the left and right lobes: is there a difference in ADC values? Acad Radiol. 2013 Apr; 20(4):440-5.
Score: 0.288
-
Diagnostic performance of PET/CT in the detection of liver metastases in well-differentiated NETs. Cancer Imaging. 2023 Apr 25; 23(1):41.
Score: 0.145
-
Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis. Eur J Radiol. 2023 Jun; 163:110803.
Score: 0.144
-
Diffusion-weighted MRI (DWI) for assessment of response to high-dose-rate CT-guided brachytherapy (HDR-BT) of hepatocellular carcinoma. Acta Radiol. 2024 Jan; 65(1):14-22.
Score: 0.143